<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547023</url>
  </required_header>
  <id_info>
    <org_study_id>57772</org_study_id>
    <nct_id>NCT04547023</nct_id>
  </id_info>
  <brief_title>Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy</brief_title>
  <official_title>Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest that the timing interval between oral intake and the 1-hour gestational&#xD;
      diabetes screen may have a significant impact on gestational diabetes screening glucose&#xD;
      levels. The investigators plan to conduct a prospective randomized trial comparing a 6-hour&#xD;
      fast versus liberal oral intake within 2 hours prior to the glucose tolerance test in&#xD;
      pregnancy in order to evaluate the effect of the fasting versus the fed state on routine&#xD;
      gestational diabetes screening results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes (GDM) complicates approximately 400,000 pregnancies in the United States&#xD;
      annually and is associated with significant adverse pregnancy outcomes, including increasing&#xD;
      the lifetime risk of type 2 diabetes. The American College of Obstetricians and Gynecologists&#xD;
      (ACOG) recommends that all pregnant women undergo GDM screening between 24-28 weeks gestation&#xD;
      utilizing a 1-hour oral glucose tolerance test that was designed to be administered without&#xD;
      regard to the last meal or time of day. However, studies suggest that the timing of one's&#xD;
      last meal prior to the 1-hour GDM screen may have a significant impact on GDM screening&#xD;
      glucose levels. In addition, providers routinely alter the timing of the 1-hour GDM screen&#xD;
      based on patients' self reported oral intake prior to the exam. The investigators plan to&#xD;
      conduct a prospective randomized trial comparing a 6-hour fast versus liberal oral intake&#xD;
      within 2 hours prior to the glucose tolerance test in pregnancy in order to evaluate the&#xD;
      effect of the fasting versus the fed state on routine GDM screening results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of positive GDM screen (&gt;= 140 mg/dL) on the 1 hour 50-g oral glucose tolerance test</measure>
    <time_frame>At 24-28 weeks of gestation</time_frame>
    <description>Incidence of positive GDM screen (&gt;= 140 mg/dL) on the 1 hour 50-g oral glucose tolerance test conducted between 24-28 weeks gestation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Diagnoses Disease</condition>
  <condition>Pregnancy in Diabetic</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>Fasting before gestational diabetes screen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed before gestational diabetes screen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fasting before gestational diabetes screen</intervention_name>
    <description>Fasting for at least 6 hours before 1-hour gestational diabetes screen.</description>
    <arm_group_label>Fasting before gestational diabetes screen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Per oral intake of food and drink</intervention_name>
    <description>Per oral intake of food and drink within 2 hours of gestational diabetes screen</description>
    <arm_group_label>Fed before gestational diabetes screen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant patients 18 years and older&#xD;
&#xD;
          2. Singleton gestation&#xD;
&#xD;
          3. Pregnancy managed at Lucile Packard Children's Hospital (LPCH) Stanford outpatient&#xD;
             obstetrics clinic&#xD;
&#xD;
          4. Planned delivery at Lucile Packard Children's Hospital (LPCH) Stanford Labor and&#xD;
             Delivery unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregestational diabetes&#xD;
&#xD;
          2. Gestational diabetes diagnosed in the 1st trimester&#xD;
&#xD;
          3. Less than 18 years of age&#xD;
&#xD;
          4. Planned delivery outside LPCH&#xD;
&#xD;
          5. Diabetes medication use prior to pregnancy&#xD;
&#xD;
          6. Inability to give informed consent&#xD;
&#xD;
          7. Chronic steroid use in pregnancy&#xD;
&#xD;
          8. Less than 24 weeks of gestation at the time of the 1 hour oral glucose tolerance test&#xD;
&#xD;
          9. Prior history of bariatric surgery&#xD;
&#xD;
         10. Multifetal gestation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yair Blumenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Yair Blumenfeld</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04547023/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

